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reporting symptoms and the differentiation of steroid-induced from ipilimumab-induced AEs under steroid treatment.
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ipilimumab infusions. This suggests that ipilimumab-induced antitumor responses can have an early onset and that severe
autoimmune reactions may reflect overtreatment.
Conclusion: The wide spectrum of ipilimumab-induced AEs demands doctor and patient awareness to reduce morbidity
and treatment costs and true ipilimumab success is dictated by both objective tumor responses and controlling severe side
effects.
Citation: Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, et al. (2013) The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4
Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE 8(1): e53745. doi:10.1371/journal.pone.0053745
Editor: H. Peter Soyer, The University of Queensland, Australia
Received September 7, 2012; Accepted December 3, 2012; Published January 14, 2013
Copyright:  2013 Voskens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study is an academic study without any external funding.
Competing Interests: The authors have read the journal’s policy and have the following conflict: Several authors are member of local and regional BMS-
ipilimumab advisory boards. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: lheinzer@post.harvard.edu
" For the ipilimumab network.
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e53745
Introduction
Ipilimumab has been shown to enhance pre-exisiting immune
responses, including antitumor responses, by directly blocking
cytotoxic T-lymphocyte antigen-4 (CTLA-4) mediated T cell
inhibition [1,2] and is now FDA and EMA approved as treatment
modality in patients with metastatic melanoma. One treatment
cycle consists of four infusions at approximately $30,000 each for a
total of $120,000 drug costs per treated patient. In general, tumor
responses are long-lasting [3], yet relatively limited with responses
in only 10–15% of patients [4,5]. However, its application is
associated with immune-related adverse events (irAEs) in up to
64% of patients [6] and detailed treatment algorithms for the
management of commonly reported side-effects are provided by
the manufacturer. Since CTLA-4 is inducibly expressed on
virtually all T cells, ipilimumab has the potential to induce irAEs
in a wide variety of tissues and organs. Single cases of
unpredictable, in part astonishing, and difficult to treat, life-
threatening or even fatal side-effects, have been reported including
cases of nephropathy [7], myopathy [8], sarcoidosis [9], Guillain-
Barre´ syndrome [10], uveitis, and leucopenia [11].
Since ipilimumab is increasingly being applied, the medical
community will be confronted with new ipilimumab-induced side
effects. To limit ipilimumab-related morbidity, stringent identifi-
cation and immediate treatment of side-effects is crucial.
Therefore, we summarized rare and difficult-to-treat ipilimu-
mab-induced side effects among 19 skin cancer centers. In
addition, we address specific hurdles, which we feel are critical
for the success of CTLA-4-based immunotherapy.
Methods
Ethics Statement
This retrospective study was approved by the local institutional
review board of the Friedrich-Alexander-Universita¨t Erlangen-
Nu¨rnberg. In addition, all clinical protocols (44 in total among 19
participating study centers) were reviewed and approved by the
local institutional review boards of each participating center and
were performed according to Good Clinical Practice (GCP) and
the Helsinki Declaration. In agreement with the local institutional
review board of the Friedrich-Alexander-Universita¨t Erlangen-
Nu¨rnberg, no written consent was obtained from included patients
since the study was conducted completely anonymous.
Study Centers and Treatment Settings
Participating study centers screened patient files for ipilimumab-
associated AEs and reported them on a template. Common AEs
(e.g., rash, colitis) were excluded. Based upon the authors’
discretion, additional information was requested for the 15 most
compelling and instructive cases. Study centers and treatment
settings are summarized in Table S1.
Results
A total of 752 melanoma patients were treated with ipilimumab
at 19 skin cancer centers and 120 AEs were reported. These
included fatigue, flu-like symptoms, rigor/chills, eosinophilia and
rashes (38 patients), which were not further evaluated. A total of 88
rare AEs in 82 patients affecting skin (23 patients), endocrine
system (14 patients), nervous system (11 patients), liver (11
patients), respiratory tract (8 patients), gastrointestinal tract (6
patients), pancreas (3 patients), sinuses (3 patients), renal system (2
patients), musculosceletal system (2 patients), heart (1 patient), eyes
(1 patient), and upper extremities (1 patient) were observed. In
addition, a systemic grade IV anaphylactoid reaction and a fatal
case of tumor mass liquefication were reported.
Skin
Ipilimumab-induced skin reactions are common, yet rarely
severe (1–4% grade 3/4 reactions). Maculopapular rashes occur in
10–50% of patients independently of dosage and pruritus has been
documented in up to 29.6% [5]. Rarely, Sweets syndrome or
Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)
have been observed (product monography). Importantly, melano-
ma-associated hypopigmentation (MAH) has been reported and
postulated to be prognostically favorable [12]; [13]. In our study
eight cases of MAH were reported (Figure 1A) and associated with
one complete response (CR), one partial response (PR), one mixed
response (MR), four stable diseases (SD) and one progressive
disease (PD).
Other reported skin reactions included prurigo, acneiform rash,
lichenoid exanthema, pyoderma gangraenosum-like ulcerations,
skin toxicity in irradiated area, photosensitivity reaction and a
drug rash with eosinophilia and systemic symptoms (DRESS) and
detailed in Table 1 and Table 2 patient 6.
Patient 1– DRESS. A 77-year old metastatic melanoma
patient was treated with ipilimumab (10 mg/kg body weight). The
second ipilimumab infusion was combined with radiotherapy of
the axillary region. Seven days after radiation, the patient
presented with fever and overall performance deterioration. Two
days thereafter, a diffuse maculo-papular rash without epidermal
splits, necrosis, or mucosal symptoms developed, which rapidly
progressed to erythrodermia without general symptoms. A
hypereosinophilia at 2300/mm3 with normal hepatic function
yet progressive renal failure (creatinine clearance 28 ml/min
versus 84 ml/min at baseline) were observed one week after onset
of the symptoms described above. A renal biopsy showed
lymphocytic nephritis, indicative for a drug-related nephritis
(Figure 1B). Oral prednisone (1 mg/kg body weight) was started
and renal function, rash and hypereosinophilia normalised within
one month. Importantly, staging showed a 40% tumor reduction.
Overall, diagnosis of an ipilimumab-induced DRESS was likely
due to the association of rash, hypereosinophilia, and renal failure
at week four after initiation of therapy.
Patient 2–Skin toxicity in radiated area. After resection of
an acrolentiginous melanoma a 59-year old patient developed
metastases of the subcutaneous tissue of her right forearm, for
which she was treated with surgery and radiotherapy. Addition-
ally, lung and adrenal gland metastases appeared. Radiotherapy
(2062.5 Gray; total 50 Gray) was started three weeks before
ipilimumab initiation while ipilimumab (3 mg/kg body weight)
was started five days before the final radiation. Five days later the
patient developed blisters within the radiated area (Figure 1C).
These symptoms completely resolved under conservative local
treatment with urea lotion and sulfadiazine silver and restaging
showed stable disease. Importantly, an adverse reaction to the
radiotherapy itself cannot be completely ruled out. However, the
timely association with the initiation of ipilimumab therapy and
the fact that no blister-formation was induced by radiotherapy
alone, is highly suggestive for an ipilimumab-induced skin toxicity
in the radiated area.
Patient 3 - Photosensitivity reaction. A 47-year old female
patient received ipilimumab in an adjuvant setting (10 mg/kg
body weight). Two weeks after the first infusion, erythematous
maculae developed in sun-exposed regions a few hours after two
short outdoor stays despite extensive sun protection (sun protection
factor 50+; ultraviolet (UV)-B/UV-A). The erythema disappeared
during the next five days. Further treatment was complicated by
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diarrhea (up to 10 times/day; treated with i.v. and subsequently
oral steroids) 37 weeks after treatment initiation. In addition,
circumscribed depigmented, non itchy areas below both knees, a
pronounced itchy rash, erythematous macules and infiltrated
plaques affecting the lumbar and inguinal region, the flexural
areas, scalp, both palms and the lower right leg, were reported.
Laboratory blood tests showed no signs of inflammation.
Histological evaluation demonstrated a spongiotic epidermis with
parakeratosis and acanthosis, a discrete edema in the dermal
papillae and a perivascular infiltrate of lympho-histiocytes with
some eosinophils. Based on these findings, a pruritic exanthema
and/or a drug eruption was postulated, which completely subsided
under treatment with topical steroids.
Gastrointestinal Tract and Pancreas
Diarrhea/colitis is a common ipilimumab-induced AE [14,15].
Severe colitis can result in bowel perforation or intractable
bleeding requiring colectomy [4,5,16–18] and is associated with
high mortality [19]. In our study, three bowel perforations, three
cases of pancreatitis and one case of asymptomatic elevation of
amylase and lipase (lipase 868 U/l; normal range 13–60 U/L,
amylase 337 U/l; normal range ,110 U/l) were reported
(Table 2). In one patient, pancreatitis was preceded by an
amenorrhea with hyperprolactemia (Table 3 patient 3).
Patient 4 - Sigma perforation. A 55-year old man with
lung, bone and lymph node melanoma metastases and a history of
diverticular disease developed diarrhea (9–10 times/day) and
cramp-like abdominal pain two weeks after the third ipilimumab
infusion (3 mg/kg body weight). Intravenous steroids were given
and symptoms improved. Since the abdomen was soft without
signs of rebound tenderness, steroids were continued orally (2 mg/
kg body weight). However, after switching to oral steroids, acute
abdominal pain with signs of peritonitis developed. Computed
tomography (CT) imaging demonstrated pneumoperitoneum
highly suspicious for a perforation. The perforated sigmoid was
resected and a colostomy was performed. Histological findings
demonstrated an exacerbated purulent diverticulitis (positive for
Prevotella intermedia, streptococci and Escherichia coli) and perforation.
Steroids were continued after surgery and subsequently tapered.
In this case the colitis initially seemed completely controlled by
intravenous (i.v.) steroid treatment, yet rapidly deteriorated under
steroid reduction. This implicates incomplete suppression of
ipilimumab-triggered autoimmune effects or masking of symptoms
under steroid treatment. Importantly, a known inflammatory
condition like diverticular disease might represent a relative
contraindication for ipilimumab. This may require special caution
with prior ultrasound examination and/or prophylactic steroid
treatment.
Patient 5 - Colonic perforation. A 74-year old melanoma
patient with progression of disease despite prior polychemo- and
radiotherapy showed a partial remission six weeks after initiation
of ipilimumab treatment (3 mg/kg body weight). Five days later
she reported diarrhea (10 times/day) that had been ongoing for
five days. Treatment with i.v. prednisolone (2 mg/kg body weight)
and loperamide (2 mg after each defecation) was initiated.
Symptoms subsided within five days and she was continued on
oral steroids (1 mg/kg body weight). After three days of oral
steroids diarrhea recurred and i.v. prednisolone treatment (2 mg/
kg body weight) was reinitiated. However, symptoms now were
steroid-refractory and despite additional therapy with infliximab
(300 mg absolute i.v.) an acute abdomen developed. A hemicol-
ectomy with colostomy was performed due to perforation of the
colon. Treatment with infliximab was continued every 6 weeks
with final amelioration of the colitis.
Patient 6 - Toxic megacolon. A 44-year old woman with
stage IV melanoma developed diarrhea (up to 30 times/day) and a
subsequent acute abdomen sixteen weeks after initiation of
ipilimumab treatment. X-ray showed ballooned bowels. A
Figure 1. Ipilimumab-induced skin reactions and nephritis.
Melanoma-associated hypopigmentation (MAH) in a patient exhibiting
a partial clinical response (A). Masson’s trichome staining showed
lymphocytic nephritis in a patient with an ipilimumab-induced drug
rash with eosinophilia and systemic symptoms (DRESS) (B). Skin toxicity
with the formation of blisters upon induction of treatment with
ipilimumab in an area that had been radiated, five weeks earlier, in a
patient with previous resection of the distal part of digit II due to an
acrolentiginous melanoma (C).
doi:10.1371/journal.pone.0053745.g001
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perforation was feared and a colostomy was performed to relief
pressure. Interestingly, the colostomy showed no signs of healing
and a revision was performed two weeks later. Histological
findings showed ulcers and a granulocytic infiltrate in the mucosa.
No bacterial or viral pathogens were found and the patient fully
recovered from this AE.
Patient 7 - Small bowel perforation. Ipilimumab treatment
(3 mg/kg body weight) was initiated in a 67-year old male with
multiple melanoma metastases. Since the patient developed
abdominal pain a colonoscopy was conducted but showed no
signs of ulceration or colitis. However, the small intestine could not
be investigated. Twelve weeks after the first ipilimumab treatment,
the patient was admitted with acute abdomen and an emergency
small bowel resection was performed. At this time, he also suffered
from purulent peritonitis, thus no steroids were given. Staging
showed a PR with regression of all metastases except bone lesions.
Detailed treatment algorithms for the management of ipilimu-
mab-induced diarrhea/colitis exist [20]. Whereas in previous
reports three out of four patients with colonic perforation were
refractory to initial treatment with high-dose steroids [21],
perforations in our study occurred after initial symptom improve-
ment and steroid reduction. Steroids should be slowly tapered (30–
60 days) and in cases of symptom recurrence, steroids should
immediately be administered i.v. and if symptoms do not improve
within 24 hours of therapy, additional immunosuppressive therapy
(e.g. infliximab) should be initiated.
Patient 8 - Ischemic gastritis. A 72-year old female
received ipilimumab (3 mg/kg body weight) due to progressive
metastatic melanoma affecting lymph nodes, subcutaneous tissue
and the gastrointestinal tract (cecum and jejunum without signs for
passage disorders). Shortly after the first infusion, the patient
underwent a complete surgical resection of all metastases with
histological confirmation of the excised lesions. After the third
infusion, the patient developed generalized pruritus including eyes
and genital mucosa, which responded to antihistamines. Staging
after the fourth treatment showed no metastases but a new strong
diffuse fluordesoxyglucose (FDG)-enhancement in the gastric wall
(most intense in the gastric corpus). Since the patient was
asymptomatic with normal S100 values, radiologic follow-up
without further action was advised. The next positron emission
tomography (PET)-CT scan demonstrated no enhancement in the
stomach mucosa. However, three months later, a strong FDG-
enhancement in the corpus of the stomach was detected again,
suggesting the presence of gastritis without further evidence of
metastases. Radiological findings and an ongoing anemia eventu-
ally causing dyspnea, prompted a gastroscopy. Biopsy showed an
ischemic gastritis compatible with the endoscopic findings
(Figure 2). No helicobacter pylori (HP) or metaplasia were
detected. Symptoms spontaneously resolved and the last PET-
CT scan detected no enhancement of the gastric wall.
Hepatitis
Hepatotoxicity is reported in 3–9% of ipilimumab patients and
usually manifests as an asymptomatic increase of transaminases
and bilirubin. Hepatitis has been reported in up to 0.8% of
patients in the first [4] and up to 1.6% in the second phase III
study [5]. Importantly, this AE can be life-threatening since one
patient with fatal liver failure has been reported [4]. Thus, high
dose steroids are recommended in case of grade 3/4 hepatotox-
icity. In our study, 11 cases of liver-related irAEs were reported
(Table 2, Table 3 patient 12; Table 4 last patient).
Patient 9– Fatal autoimmune hepatitis and nephritis. A
71-year old man with stable stage IV B-cell non-Hodgkin
lymphoma suffered from metastatic melanoma. After the second
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ipilimumab treatment, the patient presented in a reduced general
condition and with massive increase of liver transaminases and
creatinine. Systemic steroids induced a slight improvement in
liver transaminases within 24 hours. However, creatinine levels
further increased and the patient required dialysis. In addition, his
neurologic condition rapidly deteriorated with reduced responses
to his environment and reduced respiration (spontaneous oxygen-
ation below 60%). An inflammatory-induced capillary leak
syndrome completely abolished renal function. Despite full
symptomatic supportive treatment in the intensive care unit the
patient died three days after admittance. Autopsy showed necrotic
metastases and septal infiltration of the liver with CD3+
lymphocytes. This finding supports an ipilimumab-induced
reaction and is less likely induced by lymphoma progression.
Unfortunately, this hepatotoxicity described above was steroid-
refractory and resulted in fatal outcome. Importantly, successful
treatment of a fulminant hepatitis refractory to treatment with
steroids and mycophenolate mofetil with antithymocyte globulin
(1.5 mg/kg for four times) has been reported [22].
Endocrine System
IrAEs affecting the endrocrine system include euthyroid Graves
ophthalmopathy [23] and thyroid dysfunction with both hypo-
and hyperthyroidism, which can manifest as thyroiditis [24,25].
Hypophysitis is a rare, yet serious complication of ipilimumab
treatment. Incidence varies between 1.8% and 17% of patients at
the 1–3 and 10 mg/kg doses, respectively [26,27]. Symptoms
include loss of libido, fatigue, headache, memory difficulties,
dizziness, vision changes and constipation. When suspected, a
complete work-up including serum potassium, sodium, morning
cortisol, luteinizing hormone (LH), follicle stimulating hormone
(FSH), testosterone, insulin-like growth factor (IGF)-1 and free
thyroxine (fT4), as well as a brain magnetic resonance imaging
(MRI) – also to exclude brain metastases - is necessary. Pituitary
enlargement can precede clinical or laboratory evidence of an
autoimmune-mediated hypophysitis. In contrast, hypophysitis
cannot be ruled out by normal MRI findings. Upon diagnosis,
prompt steroid therapy and regular follow-up with blood tests
(serum potassium, sodium, testosterone (in men) and fT4) are
indispensable. Cortisol measurements are not informative if steroid
treatment is ongoing.
A newly diagnosed hyponaetremia or a secondary amenorrhoe
seen in a premenopausal patient (patient 3, Table 3) are suspicious
for newly developed corticotropin deficiency due to pituitary
deficiency, whereas normal menses exclude gonadotropic defi-
ciency in premenopausal women. Therapy consists of hormone
replacement. Within this study, 14 patients with endocrinological
AEs are reported including 12 cases of hypophysitis (Table 3).
Patient 10– Hypophysitis. A 74-year old male with no
history of brain metastases received ipilimumab (3 mg/kg
bodyweight) due to progressive metastatic disease affecting both
adrenal glands. Shortly after the second treatment, he showed
progressive ataxia and aphasia. MRI ruled out newly developed
brain metastases and hypophysitis was suspected. Except for a
slightly decreased testosterone, no hormonal changes were
observed. Oral steroids (dexamethasone) were started and
tapered. After two weeks, a decrease in thyroid hormones and
testosterone was noted. Due to steroid therapy, the likewise
decreased cortisol levels could not be used for interpretation. A
second MRI demonstrated improvement of the morphological
changes. Thyroid-hormone substitution was initiated and
steroids tapered. After discontinuing steroid treatment, progres-
sive ataxia and aphasia developed again. At this time,
laboratory findings revealed hyponatraemia (serum sodium
Figure 2. Ipilimumab-induced ischemic gastritis. Hematoxillin
eosin staining showed edematous hypervascularized lamina propria
mucosae, foveolar hyperplasia and regenerative basal crypts at 106
magnification (A) and 506magnification (B). Endoscopic narrow band
imaging (NBI) showed signs of reactive chronic inflammation of the
gastric corpus mucosa with prominent vascular pattern consistent with
an ischemic gastritis (C). Positron emission tomography (PET) scan
illustrated high level tracer uptake in the gastric wall consistent with
inflammation (D) and its spontaneous resolution after four months with
a remaining thickening of the gastric wall (E).
doi:10.1371/journal.pone.0053745.g002
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125 mmol/l, normal range 135–145 mmol/l), and reduced
levels of cortisol (2.6 mg/dl, normal range 5–25 mg/dl), testos-
terone (0.5 ng/ml, normal range 2.8–8.5 ng/ml) and dehydroe-
piandosterone (DHEAS) (,150 ng/ml, normal range 800–
5000 ng/ml). Adrenocorticotropic hormone (ACTH), LH, pro-
lactin, free triiodothyronine (fT3) and fT4 (under treatment with
thyroid hormones) were normal. A third MRI showed similar
results to the second MRI scan, but pituitary impairment
persisted. Under i.v. steroids (dexamethasone 464 mg) ataxia
and aphasia subsided and serum sodium levels normalized. In
conclusion, the observed hyponatraemia appeared due to an
acute Addison crisis after steroid withdrawal because of
persisting corticotropin deficiency. Although the clinical course
was further complicated by a steroid-induced psychosis and a
bacterial infection of unknown origin, the patient is now free of
symptoms under hormonal substitution with thyroid hormones,
hydrocortisone and testosterone.
Patient 11 - Hypophysitis with brain edema. A 67-year
old man with multiple melanoma metastases received stereotactic
irradiation for a single parietooccipital brain metastasis (4 mm
diameter) and developed a new cerebellar metastasis. Four
consecutive treatments with ipilimumab (3 mg/kg body weight)
were well tolerated apart from a slight decrease in thyroid-
stimulating hormone (TSH) (0.3 mU/l; normal range: 0.4–
4.9 mU/l) with normal fT4 before the third treatment. After the
third treatment the cerebellar metastasis was stereotactically
irradiated. Fourteen weeks after initiation of ipilimumab, the
patient presented with acute onset of nausea, dizziness and ataxia.
On examination, a blurred speech was noticed, prolactin was
elevated with 30.7 ng/ml (normal range 3.5–19.5 ng/ml), cortisol
and TSH were decreased with ,1.0 mg/dl (normal range 4.3–
22.4 mg/dl) and 0.27 mU/l (normal range 0.4–4.9 mU/l), respec-
tively. CT scan showed the previously described irradiated
metastases with adjacent edema as well as an increase in volume
of the pituitary gland with signs of brain edema. Under i.v. steroid
treatment (dexamethasone 16 mg/day) symptoms ameliorated.
In agreement with previous reports, 4 out of 12 hypophysitis
patients require ongoing hydrocortisone replacement and in some
cases additionally thyroid hormones and testosterone/estrogen
[28,29].
Nervous System
Ipilimumab-associated neurological symptoms are rare, but
may be life-threatening. Common symptoms include headache,
dizziness, lethargy, and asthenia. Rarely, patients present with
cranial neuropathy and optic nerve ischemia, ataxia, tremor,
myoclonia, dysarthria and peripheral neuropathy. Importantly,
Guillian-Barre´ syndrome was described twice [30] with fatal
outcome in one patient [4]. In addition, meningo-radiculo-neuritis
[31], enteric neuropathy [32] and cerebral edema with convul-
sions [33] have been reported.
Six out of eleven rare neurological AEs reported in this study
required immunosuppression (Table 5, last patient Table 6). In
general, steroid treatment was effective although one patient
experienced a therapy-refractory neuropathy and eventually died
despite additional treatment with intravenous immunoglobulin
(IVIG).
Patient 12– Granulomatous inflammation of the central
nervous system (CNS). A 50-year old man with stage IIIA
melanoma experienced transient chills without fever eight weeks
after initiation of ipilimumab. In addition, two weeks later right-
sided facial paresthesia and muscle weakness in both legs were
observed. Paresthesia in his face deteriorated and extended to the
whole face. Additionally, singultus and nausea appeared and
persisted. Twelve weeks after start of ipilimumab, his neurological
condition suddenly worsened resulting in sensoric ataxia and a
disabling progressive paraparesis affecting both legs. All examina-
tions for bacterial, fungal and viral causes were negative. No
melanoma cells could be detected by lumbar puncture, and a
marked lymphocytic pleocytosis was seen. Blood CD4/CD8 ratio
was markedly increased at 4.3 (normal range 1.1–3.0) with an
increase of absolute CD4-lymphocytes (1.8/nl; normal range 0.5–
1.2/nl). The MRI showed an enhancement in both trigeminal
nerves and, additionally, three parenchymal lesions with no
indication for meningiosis carcinomatosa or pituitary enlargement.
Because of suspected ipilimumab-induced granulomatous disease
high dose steroids were initiated and quickly improved symptoms.
Brain lesions disappeared in a subsequent MRI and symptoms
completely resolved.
Patient 13– Tolosa-Hunt-Syndrome. A 65-year old male
patient with primary skin melanoma without brain metastases or
thyroid disease received ipilimumab (3 mg/kg body weight) due to
progressive metastatic melanoma. Eighteen weeks after the first
dose of ipilimumab, the patient presented with acute onset of
strong pain above his right eye that radiated to the paranasal sinus,
epiphora and double vision. In addition, dizziness and nausea was
reported. The ophthalmologist recorded a mydriasis of the right
pupil and a ptosis with paresis of the oculomotorius nerve leading
to limited mobility and inability to completely open the right eye,
compatible with a Tolosa-Hunt-Syndrome. Brain MRI revealed a
markedly prominent neural sheath of the right optic nerve, no
alteration in the cavernous sinus and no metastases. Except for a
stable anemia and an increased CRP (54 mg/l, normal range
,5 mg/l), laboratory values were within normal range with
normal TSH and negative thyroid autoantibodies. Interestingly,
an unclear FDG-enhancement in the left thyroidal lobe had been
previously detected by FDG-PET/CT. High-dose steroids (initial-
ly i.v. methylprednisolone and subsequently oral dexamethasone)
and local radiotherapy (1063 Gray) was simultaneously started.
This treatment combination markedly and promptly reduced the
ocular pain and paresis but showed only little impact on the vision
disturbances. Staging showed progressive disease with new liver
metastases.
Patient 14– Aseptic meningitis. A 52-year old female with
melanoma metastases affecting lymph nodes, soft tissue, liver, and
bones (sacral vertebra, 2 ribs and temporal bone) presented with
nausea, vomiting, chills and rash, three weeks after the first
ipilimumab infusion. Therapy included rehydration, antiemetics,
novaminsulfon and topical steroids. One week later, she presented
with agitation, disorientation, aggressive behaviour and the
inability to make contact with other people. Since she was
screaming and physically attacking the physicians, a blood draw
required four people holding the patient in addition to sedation
with esketamin (50 mg) and midazolam (15 mg). Body tempera-
tures had risen to 39uC but no signs of meningism were observed.
Treatment with i.v. ceftriaxon, ampicillin as well as acyclovir and
dexamethasone was initiated. Liquor analyses revealed mostly
lymphomonocytic cells (mainly CD3-positive lymphocytes) and
excluded a meningiosis neoplastica or herpes simplex infection.
Brain MRI showed four new brain metastases (,1 cm in diameter
each) and an accentuation of the temporal bone metastasis. After
electroencephalography (EEG), transcranial ultrasound, and
repeated liquor examinations, an aseptic ipilimumab-induced
meningitis was suspected. Ipilimumab treatment was permanently
discontinued and symptoms resolved completely. Unfortunately,
the patient demonstrated disease progression despite subsequent
gamma knife and fotemustine treatment.
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Physicians should be aware that neurologic symptoms can
exacerbate unexpectedly at any time. The patient described above
would have died of meningitis if no relatives would have been
around. Importantly, it has been reported that prior therapy with
neurotoxic agents may increase the risk of neurological-related
adverse reactions [30], however, these findings are not confirmed
in our study population.
Respiratory Tract and Renal System
Reported ipilimumab-induced respiratory tract-related adverse
reactions include a life-threatening pneumonitis after allogeneic
hematopoietic cell transplantation [34], fatal acute respiratory
distress syndrome (product monography), pulmonary granuloma-
tosis [35] and sarcoidosis [9,36,37]. Observed rare respiratory-
tract irAEs, included barky rhinitis, alveolitis and atypical
pneumonia (Table 6). Ipilimumab-induced respiratory tract-
related irAEs have significant clinical implications, since they
may be life-threatening. In addition, radiological signs of
sarcoidosis can be confused with pulmonary metastases [38]
resulting in inadequate change of therapy.
Adverse reactions affecting the renal tract are rare [7]. In this
study two cases of acute renal failure were reported (Table 6). Both
responded well to steroid treatment and resolved without sequelae.
Miscellaneous
It remains unclear why different targets are affected during
ipilimumab treatment. In the literature, hemophilia A [39] and
autoimmune polymyositis [40] have been reported.
In our study, eleven patients presented with AEs not related to
skin, liver, endocrine system, respiratory tract, kidney, or nervous
system (Table 4). Interestingly, one patient showed myocardial
fibrosis in conjunction with hepatitis (Figure 3). Importantly, one
patient experienced an anaphylactoid reaction with flush, diffuse
muscle contractions, chest tightness, hypertension, tachycardia
and tachypnoe after infusion of 20% of the total ipilimumab
volume of the second infusion. Symptoms resolved upon treatment
with i.v. steroids and antihistamines. To the best of our knowledge,
this is the first reported grade IV anaphylactoid reaction to
ipilimumab.
Patient 15 - Tumor mass liquefication. A 66-year old
male patient presented with progressive left-sided iliac lymph node
metastases and bulky tumor growth on the left-sided abdomen, the
groin and left thigh despite lymph node dissection, hyperthermal
limb perfusion, dacarbazine monochemotherapy, polychemother-
apy with temozolomide, vindesine and cisplatin and fotemustine.
In addition, arterial and venous compression, infiltration and
thrombosis led to a massive increase of the pre-existing lymph
edema of the left leg. An attempt of brachytherapy failed. Upon
the second treatment with ipilimumab, the patient reported a
considerable reduction of the tumor mass and lymph edema. At
this time, the tumor bulk on the left-sided abdomen showed two
ulcerations with minimal foetid secretion (Figure 4A). Four weeks
later, tumor infiltration and lymph edema of the left leg were
nearly resolved. Both ulcerations were still present and sore.
Abdominal examination revealed a ballottement and a highly
inflammatory induration of the entire lower abdominal wall. No
hyperphosphatemia, hyperkalemia, hyperuricemia or hypocalce-
mia were observed. An ultrasound-guided tumor incision on the
right side of the abdomen released approximately 400 ml of a
liquefied, partially necrotic and putrefied tumor bulk. Further CT-
controlled drainage of the abdominal mass did not result in any
improvement and the patient unfortunately died shortly after the
third treatment despite antiseptic treatment including broad
spectrum antibiotics, presumably as a consequence of septicaemia.
This case illustrates ipilimumab’s potential to induce strong
antitumor immune responses with rapid and sustained tumor
destruction (Figure 4B–C). Tumor destruction releases antigens,
including non-self antigens as well as endogenous danger signals,
which trigger inflammation, cytokine release and the infiltration of
immune cells in the tumor-affected organs. Extended inflamma-
tion, tumor destruction and necrosis may induce multi-organ
failure similar to a tumor lysis syndrome.
Discussion
This study summarizes unexpected and rare ipilimumab-
induced AEs. To our knowledge, we report for the first time on
(i) rare skin reactions, including a DRESS, a photosensitivity
reaction and skin toxicity in a previously radiated area, (ii) a case of
ischemic gastritis, (iii) rare neurological reactions, including
granulomatous CNS inflammation, a Tolosa-Hunt-Syndrome
and aseptic meningitis and (iv) a case of tumor mass liquefication
with fatal outcome. Furthermore, we report on three intestinal
perforations of which one was masked by ongoing steroid therapy,
one occurred despite therapy with steroids and infliximab and one
occurred in the small intestine outside the endoscopic examination
range. In addition, different courses of ipilimumab-induced
hypophysitis are described. Time course of specific side effects
differed with e.g., much earlier onset of hepatitis than previously
reported [20].
Since ipilimumab-induced irAEs can virtually affect any organ
system physicians have to consider all symptoms as potentially
ipilimumab-associated. In turn, patients have to be instructed to
report all symptoms even if deemed unrelated. Several centers
experienced difficulties in patient compliance with reporting AEs.
For example, patients with severe diarrhea mostly reported
symptoms several days after onset, which in one case resulted in
a colonic perforation. As compliance of patients is limited when
they fear their treatment will be stopped due to AEs, the fact that
treatment efficacy is not abrogated despite steroid treatment
should be stressed [41,42]. In the case of ipilimumab-induced
irAEs prompt steroid treatment reduces intensity and duration of
symptoms [43]. Even conditions that classically do not respond to
steroid treatment, like Guillain-Barre´ syndrome [30] or hypophy-
sitis, readily respond if ipilimumab-induced. Among all 120
evaluated patients in this study, side effects resolved in 82 cases.
In 22 patients, side effects are ongoing and in 13 patients
permanent changes remained. Unfortunately, three ipilimumab-
induced fatalities occurred despite treatment.
Side effects caused by other drugs have to be differentiated from
ipilimumab-induced irAEs as seen in patient 10 with psychological
symptoms, first due to an ipilimumab-induced hypophysitis and
later due to steroid treatment. Similarly, steroid-induced myopa-
thy in a colitis patient can resemble an irAE. Thus, in order to
avoid steroid-induced side effects in prolonged autoimmune
reactions, a switch to other immunosuppressants, like etanercept,
infliximab, or mycophenolat mofetil may be advisable. Further-
more, skin- and gut-related adverse reactions may reflect immune
activation in response to signals from commensal organisms [44].
However, in the skin immunoactivation through commensal
microflora seems less likely, since most ipilimumab-induced skin
reactions morphologically show exanthema, rather than eczema.
In patients with colitis, detailed studies addressing antigen-
specificity of ipilimumab-induced immune reactions are needed
to distinguish autoimmunity from an enhanced reaction to
resident flora.
Frequency and severity of irAEs seem to be dose-dependent
[12,13]. However, immunotherapeutics in general do not show
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linear dose response curves since induction of immunity
depends on the host’s immune system. Limited data exists to
predict response or identify patients who are likely to develop
severe irAEs. CTLA-4 polymorphism may play a role [45]
although clear evidence is still pending [46]. Importantly,
genetic predisposition for the development of autoantibodies is
postulated since mice expressing specific CTLA-4 isoforms
developed spontaneous autoimmunity, including elevated
production of autoantibodies [47]. In addition, anti-CTLA-4
antibodies have been shown to induce autoantibodies in mice
[48] and CTLA-4 specific autoantibodies have been found in
sera from patients suffering from various autoimmune diseases,
including systemic lupus erythematosus, rheumatoid arthritis,
systemic sclerosis, Behc¸et’s disease and Sjo¨gren’s syndrome
[49]. Although autoantibodies may be generated in vivo by an
antigen-dependent mechanism and are postulated to modulate
immune responses by interfering with CTLA-4 on T cells, it
remains unclear whether CTLA-4 specific autoantibodies
contribute to or protect against autoimmune reactions. Future
studies in patients undergoing ipilimumab-treatment will be
necessary to elucidate this question.
Interestingly, several large studies reported increased effica-
cy in patients affected by irAEs [21,42,50–52] with responses
in 26% of patients experiencing any irAE compared to 2% in
patients, who did not experience any irAE [42]. There also was
a ‘severity-response-effect’ with response rates of 22% and
28%, in patients with grade 1/2 and grade 3/4 adverse
reactions, respectively [42]. Nevertheless, clinical responses are
Figure 3. Ipilimumab-induced myocardial fibrosis in conjunction with hepatotoxicity. Hematoxillin eosin staining at 506magnification
(A), 2006magnification (B) and 4006magnification (C) and chloracetate esterase staining at 506magnification (D), 2006magnification (E) and 4006
magnification (F) revealed neutrophilic granulocytes (black arrow) mostly around the central vein (asterisk). Portal fields were almost normal (white
arrows). Some necrotic hepatocytes (black arrow heads panel C) and cholestasis of hepatocytes (white arrow heads panel C) indicating liver
insufficiency, were detected pericentrally. Slightly elevated myocardial fibrosis (white arrow heads panel F) surrounded by structural changes of
cardiomyocytes were detected (black arrow heads panel F).
doi:10.1371/journal.pone.0053745.g003
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also seen in patients treated with ipilimumab without any irAE
[50]. Furthermore, it is unclear whether four infusions as
currently approved for treatment are necessary to induce
tumor response. In patients where treatment was interrupted
due to irAEs, clinical benefit was already observed after 1–3
ipilimumab infusions. This suggests that in a subgroup of
patients fewer infusions might be sufficient to boost pre-
existing anti-tumor immunity. A reduced number of infusions -
if proven effective - could reduce costs as well as associated
irAEs.
In our study, tumor regression was observed in 30.9% (21
out of 69) and tumor control in 61.8% (42 out of 69) of stage
IV patients. No association was observed between organ
system affected by the side effect and organ system that
responded to therapy. Since ipilimumab can only augment
existing T-cell responses, a previous tumor-specific immune
response is indispensable [53] and could be induced by prior
antigen-specific immunotherapy.
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